Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Da Silva

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Investigation|March 10, 2015
Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patientsIsabelle Magalhaes, Karine Pingris, Christine Poitou, et al.
Science Translational Medicine|March 27, 2024
The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritisPatrick J Gleeson, Nicolas Benech, Jonathan Chemouny, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 28, 2020
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung functionPierre-Régis Burgel, Isabelle Durieu, Raphaël Chiron, et al.
The European Respiratory Journal|January 19, 2024
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare <i>CFTR</i> variants: a viewpointPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.
The Lancet. Respiratory Medicine|August 16, 2024
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world studyPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 25, 2025
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF studyAnne-Sophie Bonnel, Tiphaine Bihouée, Mélanie Ribault, et al.
The European Respiratory Journal|February 16, 2023
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del <i>CFTR</i> variantPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, et al.
The European Respiratory Journal|September 11, 2023
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescriptionElise Dreano, Pierre Régis Burgel, Aurelie Hatton, et al.
Frontiers in Pharmacology|November 14, 2025
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTRIwona Pranke, Valeria Capurro, Benoit Chevalier, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Investigation|March 10, 2015
Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patientsIsabelle Magalhaes, Karine Pingris, Christine Poitou, et al.
Science Translational Medicine|March 27, 2024
The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritisPatrick J Gleeson, Nicolas Benech, Jonathan Chemouny, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 28, 2020
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung functionPierre-Régis Burgel, Isabelle Durieu, Raphaël Chiron, et al.
The European Respiratory Journal|January 19, 2024
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare <i>CFTR</i> variants: a viewpointPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.
The Lancet. Respiratory Medicine|August 16, 2024
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world studyPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 25, 2025
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF studyAnne-Sophie Bonnel, Tiphaine Bihouée, Mélanie Ribault, et al.
The European Respiratory Journal|February 16, 2023
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del <i>CFTR</i> variantPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, et al.
The European Respiratory Journal|September 11, 2023
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescriptionElise Dreano, Pierre Régis Burgel, Aurelie Hatton, et al.
Frontiers in Pharmacology|November 14, 2025
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTRIwona Pranke, Valeria Capurro, Benoit Chevalier, et al.
Pageof 5